Latanoprost/Timolol (Timolol Maleate, Latanoprost)

• Latanoprost/Timolol is indicated for conditions affecting intraocular pressure within the glaucoma disease family.
• Primary open‑angle glaucoma: reduces intraocular pressure to help prevent optic nerve damage.
• Ocular hypertension: lowers eye pressure to reduce the risk of progression to glaucoma.
• Secondary open‑angle glaucoma: assists in controlling pressure when other causes are present.

• Timolol maleate acts as a non‑selective β‑adrenergic antagonist, decreasing aqueous humor production, while latanoprost, a prostaglandin F2α analog, enhances uveoscleral outflow of aqueous humor. The combined actions result in a synergistic reduction of intraocular pressure.

Latanoprost/Timolol may cause ocular and systemic adverse reactions.

Common Side Effects

• Eye irritation or burning sensation
• Blurred vision after instillation
• Redness of the conjunctiva
• Itching or mild allergic reaction
• Dry eye or foreign‑body sensation
• Transient changes in eyelash growth

Serious or Rare Side Effects

• Severe allergic reaction (angio‑edema, anaphylaxis)
• Worsening of glaucoma or sudden loss of vision
• Persistent eye pain with visual disturbance
• Systemic β‑blocker effects such as bradycardia, hypotension
• Bronchospasm in patients with asthma or COPD
• Corneal ulceration or infection

• Before prescribing Latanoprost/Timolol, consider the following safety measures.
• Assess cardiovascular status: evaluate for bradycardia, heart block, asthma or COPD.
• Monitor intraocular pressure: schedule regular ophthalmic examinations.
• Avoid in sulfonamide allergy: consider alternative therapy if hypersensitivity is known.
• Do not combine with other prostaglandin analogs: risk of additive ocular effects.
• Store at room temperature: keep in the original container, protect from light and moisture.

Latanoprost/Timolol can interact with other medications; awareness of major and moderate interactions is important.

Major Interactions (Avoid)

• Non‑selective systemic beta‑blockers (e.g., propranolol): may cause excessive systemic β‑blockade.
• Other intraocular pressure‑lowering agents (e.g., apraclonidine): risk of over‑reduction of pressure.
• Sympathomimetic eye drops (e.g., phenylephrine): may antagonize the drug's effect.

Moderate Interactions (Monitor Closely)

• Systemic carbonic anhydrase inhibitors: may enhance intraocular pressure reduction.
• Anticholinergic drugs: may affect pupil size and ocular dynamics.